Recent developments in antitumour platinum coordination compounds

Bibliography

• BRABEC V, KASPARKOVA J: Platinum-based drugs. In: Metallotherapeutic drugs and metal-based diagnostic agents. Gielen M, Tiekink ER (Eds). Wiley VC, Chichester (2005):489-506.
   Google Scholar
• DESOIZE B, MADOULET C: Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. (2002) 42:317-325.
   PubMed Web of Science ®Google Scholar
• McEVOY (Ed.). AHFS Drug Information, American Society of Heath–System Pharmacists, Bethesda (2000).
   Google Scholar
• BOULIKAS T, VOUGIOUKA M: Cisplatin and platinum drugs at the molecular level (Review). Oncol. Rep. (2003) 10:1663-1682.
   PubMed Web of Science ®Google Scholar
• MARKMAN M: Toxicities of the platinum antineoplastic agents. Expert Opin. Drug Saf. (2003) 2:597-607.
   PubMedGoogle Scholar
• AKIYAMA S-I, CHEN Z-S, SUMIZAWA T, FURUKAWA T: Resistance to cisplatin. Anti-Cancer Drug Des. (1999) 14:143-151.
   PubMedGoogle Scholar
• GALANSKI M, JAKUPEC MA, KEPPLER BK: Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem. (2005) 12:2075-2094.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, FAIVRE S, CHANEY S, WOYNAROWSKI J, CVITKOVIC E: Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. (2002) 1:227-235.
   PubMed Web of Science ®Google Scholar
• BRABEC V, KASPARKOVA J: DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action. In: Metal Complexes in Cancer Chemotherapy. Perez JM, Fuertes MA, Alonso C (Eds). Research Signpost, Kerala (2005):187-218.
   Google Scholar
• BRABEC V, KASPARKOVA J: Modification of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updates (2005) 8:131-146.
   PubMed Web of Science ®Google Scholar
• MITKOVA E, UGRINOVA I, PASHEV IG, PASHEVA EA: The inhibitory effect of HMGB-1 protein on the repair of cisplatin-damaged DNA is accomplished through the acidic domain. Biochemistry (2005) 44:5893-5898.
   PubMed Web of Science ®Google Scholar
• TORIGOE T, IZUMI H, ISHUGICHI H et al.: Cisplatin resistance and transcription factors. Curr. Med. Chem.- Anti-Cancer Agents (2005) 5:15-27.
   PubMedGoogle Scholar
• ZHANG L, HANIGAN M: Role of cysteine S-conjugate β-lyase in the metabolism of cisplatin. J. Pharmacol. Exp. Ther. (2003) 306:988-994.
   PubMed Web of Science ®Google Scholar
• AMTMANN E, ZÖLLER M, WESCH H, SCHILLING G: Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother. Pharmacol. (2001) 47:461-466.
   PubMed Web of Science ®Google Scholar
• FRIEBOLIN W, SCHILLING G, ZÖLLER M, AMTMANN E: Synthesis and structure–activity relationship of novel antitumoral platinum xanthate complexes. J. Med. Chem. (2004) 47:2256-2263.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, ROTIN D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. (1989) 49:4373-4384.
   PubMed Web of Science ®Google Scholar
• MARZANO C, TREVISAN A, GIOVAGNINI L, FREGONA D: Synthesis of a new platinum(II) complex: anticancer activity and nephrotoxicity in vitro. Toxicol. In Vitro (2002) 16:413-419.
   PubMed Web of Science ®Google Scholar
• MARZANO C, BETTIO F, BACCICHETTI F, TREVISAN A, GIOVAGNINI L, FREGONA D: Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem. Biol. Interact. (2004) 148:37-48.
   PubMed Web of Science ®Google Scholar
• FREGONA D, GIOVAGNINI L, RONCONI L et al.: Pt(II) and Pd(II) derivatives of ter-butylsarcosinedithio- carbamate. Synthesis, chemical and biological characterization and in vitro nephrotoxicity. J. Inorg. Biochem. (2003) 93:181-189.
   PubMed Web of Science ®Google Scholar
• HOLFORD J, RAYNAUD F, MURRER BA et al.: Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex cis[amminedichloro(2-methyl- pyridine)]platinum(II) (AMD473). Anticancer Drug Des. (1998) 13:366-373.
   Google Scholar
• HOLFORD J, SHARP SY, MURRER BA et al.: In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer. (1998) 77:1-18.
   Google Scholar
• GELMON KA, STEWART D, CHI KN et al.: A Phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Annal. Oncol. (2004) 15:1115-1122.
   PubMed Web of Science ®Google Scholar
• MUNK VP, DIAKOS CI, ELLIS LT, FENTON RR, MESSERLE BA, HAMBLEY TW: Investigations into the interactions between DNA and conformationally constrained pyridylamineplatinum(II) analogues of AMD473. Inorg Chem. (2003) 42:3582-3590.
   PubMed Web of Science ®Google Scholar
• CONRAD ML, ENMAN JE, SCALES SJ et al.: Synthesis, characterization, and cytotoxicities of platinum(II) complexes bearing pyridinecarboxaldimines containing bulky aromatic groups. Inorg. Chim. Acta. (2005) 358:3-69.
   Google Scholar
• OKADA T, EL-MEHASSEB IM, KODAKA M, TOMOHIRO T, OKAMOTO K, OKUNO H: Mononuclear platinum(II) complex with 2-phenylpyridine ligands showing high cytotoxicity against mouse sarcoma 180 cells acquiring high cisplatin resistance. J. Med. Chem. (2001) 44:4661-4667.
   PubMed Web of Science ®Google Scholar
• HALL MD, HAMBLEY TW: Platinum(IV) coordination compounds: their bioinorganic chemistry. Coord. Chem. Rev. (2002) 232:49-67.
   Web of Science ®Google Scholar
• KWON YE, WHANG KJ, PARK YJ et al.: Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes. Bioorg. Med. Chem. (2003) 11:1669-1676.
   PubMed Web of Science ®Google Scholar
• KWON YE, KIM K-H: Octahedral Pt(IV) complex K101 induces apoptosis via ERK1/2 activation and the p53 pathway in human colon cancer cells. Anticancer Drugs (2006) 17:553-558.
   PubMed Web of Science ®Google Scholar
• ZAK F, TURANEK J, KROUTIL A et al.: Platinum(IV) complex with adamantylamine as nonleaving group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cell lines. J. Med. Chem. (2004) 47:761-763.
   PubMed Web of Science ®Google Scholar
• HORVATH V, BLANAROVA O, SVIHALKOVA-SINDLEROVA L et al.: Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol. Oncol. (2006)102(1):32-40.
   PubMedGoogle Scholar
• JEON YJ, KIM S-Y, KO YH, SAKAMOTO S, YAMAGUCHI K, KIM K: Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug. Org. Biomol. Chem. (2005) 3:2122-2125.
   PubMed Web of Science ®Google Scholar
• WHEATE NJ, DAY AI, BLANCH RJ, ARNOLD AP, CULLINANE C, COLLINS JG: Multi-nuclear platinum complexes encapsulated in cucurbit[n]uril as an approach to reduce toxicity in cancer treatment. Chem. Commun. (Camb.). (2004) 2004:1424-1425.
   Google Scholar
• WHEATE NJ, BUCK DP, DAY AI, COLLINS JG: Cucurbit[n]uril binding of platinum anticancer complexes. Dalton Trans. (2006) 2006:451-458.
   Google Scholar
• FARELL N, QU Y, BIERBACH U, VALSECCHI M, MENTA E: Structure–activity relationships within di- and trinuclear platinum Phase-I clinical anticancer agents. In: Cisplatin–Chemistry and Biochemistry of a Leading Anticancer Drug. Lippert B (Ed.) Verlag Helvetica Chimica Acta, Zürich (1999):479-496.
   Google Scholar
• SERVIDEI T, FERLINI C, RICCARDI A et al.: The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur. J. Cancer (2001) 37:930-938.
   PubMed Web of Science ®Google Scholar
• QU Y, SCARSDALE NJ, TRAN M, FARELL NP: Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites. J. Biol. Inorg. Chem. (2003) 8:19-28.
   PubMed Web of Science ®Google Scholar
• HARRIS AL, YANG X, HEGMANS A et al.: Synthesis, characterization and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. Inor. Chem. (2005) 44:9598-9600.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA LJ, SEABRA M, REIS E et al.: Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates. J. Med. Chem. (2004) 47:2917-2925.
   PubMed Web of Science ®Google Scholar
• KOMEDA S, LUTZ M, SPEK AL, CHIKUMA M, REEDIJK J: New antitumor-active azole-bridged dinuclear platinum(II) complexes: synthesis, characterization, crystal structures, and cytotoxic studies. Inorg. Chem. (2000) 39:4230-4236.
   PubMed Web of Science ®Google Scholar
• TELETCHEA S, KOMEDA S, TEUBEN JM, ELIZONDO-RIOJAS MA, REEDIJK J, KOZELKA J: A pyrazolato-bridged dinuclear platinum(II) complex induces only minor distortions upon DNA-binding. Chemistry (2006) 12:3741-3753.
   PubMed Web of Science ®Google Scholar
• KOMEDA S, KALAYDA GV, LUTZ M et al.: New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin. J. Med. Chem. (2003) 46:1210-1219.
   PubMed Web of Science ®Google Scholar
• XIN ZHANG C, LIPPARD SJ: New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. (2003) 7:481-489.
   PubMed Web of Science ®Google Scholar
• MOMEKOV G, BAKALOVA A, KONSTANTINOV S, TODOROV D, KARAIVANOVA M: Comparative assessment of the cytotoxic effects of carboxylato-bridged dinuclear platinum(II) complexes against human tumor cell lines. Neoplasma (2005) 52:469-475.
   PubMed Web of Science ®Google Scholar
• MOMEKOV G, FERDINANDOV D, BAKALOVA A, ZAHARIEVA M, KONSTANTINOV S, KARAIVANOVA M: In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands. Arch. Toxicol. (2006) 80(9):555-560
   PubMedGoogle Scholar
• RADULOVIC S, TESIC Z, MANIC S: Trans-platinum complexes as anticancer drugs: recent developments and future prospects. Curr. Med. Chem. (2002) 9:1611-1618.
   PubMed Web of Science ®Google Scholar
• NAJAJREH Y, PEREZ JM, NAVARRO-RANNINGER C, GIBSON D: Novel soluble cationic trans-diamminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J. Med. Chem. (2002) 45:5189-5195.
   PubMed Web of Science ®Google Scholar
• PROKOP R, KASPARKOVA J, NOVAKOVA O et al.: DNA interactions of new antitumor platinum complexes with trans-geometry activated by a 2-methylamine or sec-butylamine ligand. Biochem. Pharmacol. (2004) 67:1097-1104.
   PubMed Web of Science ®Google Scholar
• VAN ZUTPHEN S, REEDIJK J: Targeting platinum anti-tumour drugs: overview of strategies employed to reduce systemic toxicity. Coord. Chem. Rev. (2005) 249:2845-2853.
   Web of Science ®Google Scholar
• BARUAH H, BARRY CG, BIERBACH U: Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. Curr. Topics Med. Chem. (2004) 4:1537-1549.
   PubMed Web of Science ®Google Scholar
• BOULIKAS T: Low toxicity and anticancer activity of a novel liposomal cisplatin (lipoplatin) in mouse xenografts. Oncol. Rep. (2004) 12:3-12.
   PubMed Web of Science ®Google Scholar
• BOULIKAS T, STATHOPOULOS GP, VOLAKAKIS N, VOUGIOUKA M: Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. (2005) 25:3031-3039.
   PubMed Web of Science ®Google Scholar
• FEDIER A, POYET C, PERUCCHINI D, BOULIKAS T, FINK D: LH1-deficient tumor cells are resistant to lipoplatin, but retain activity to lipoxal. Anticancer Drugs (2006) 17:315-323.
   PubMed Web of Science ®Google Scholar
• IINUMA H, MARUYAMA K, OKINAGA K et al.: Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer (2002) 99:130-137.
   PubMed Web of Science ®Google Scholar
• GENG L, OSUSKY K, KONJETI S, FU A, HALLAHAN D: Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay. J. Control Release (2004) 99:369-381.
   PubMed Web of Science ®Google Scholar
• ANDRESEN TL, JENSEN SS, KAASGAARD T, JORGENSEN K: Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr. Drug Deliv. (2005) 2:353-362.
   PubMedGoogle Scholar
• APV: Drug Delivery Focus Group Newsletter (2006) 2006:1-10.
   Google Scholar
• LU C, PEREZ-SOLER R, PIPERDI B et al.: Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2005) 23:3495-3501.
   PubMed Web of Science ®Google Scholar
• HAN I, KIM OJ, LEE GY et al.: Enhanced antitumor activity of trans(+/-)-1,2-di- aminocyclo-hexaneglutamatoplatinum(II) formulated with stealth liposome. Bioorg. Med. Chem. (2003) 11:5443-5447.
   PubMed Web of Science ®Google Scholar
• RADEMAKER-LAKHAI JM, TERRET C, HOWELL SB et al.: A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. (2004) 10:3386-3395.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA N, OKAZAKI S, CABRAL H et al.: Novel cisplatin- incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. (2003) 63:8977-8983.
   PubMed Web of Science ®Google Scholar
• ARONOV O, HOROWITZ AT, GABIZON A, GIBSON D: Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem. (2003) 14:563-574.
   PubMed Web of Science ®Google Scholar
• ARONOV O, HOROWITZ AT, GABIZON A, FUERTES MA, PEREZ JM, GIBSON D: Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues. Bioconjug Chem. (2004) 15:814-823.
   PubMed Web of Science ®Google Scholar
• JUN YJ, KIM JI, JUN MJ, SOHN YS: Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene-platinum(II) conjugates. J. Inorg. Biochem. (2005) 99:1593-1601.
   PubMed Web of Science ®Google Scholar
• CASSINO C, GABANO E, RAVERA M et al.: Platinum(II) and technecium(I) complexes anchored to ethynylestradiol: a way to drug targeting and delivery. Inorg. Chim. Acta (2004) 357:2157-2166.
   Web of Science ®Google Scholar
• GABANO E, CASSINO C, BONETTI S et al.: Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes. Org. Biomol. Chem. (2005) 3:3531-3539.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ MF, MACIAS RIR, IZCO-BASURKO I et al.: Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther. (2001) 297:1106-1112.
   PubMed Web of Science ®Google Scholar
• MONTE MJ, BALLESTERO MR, BRIZ O, PEREZ MJ, MARIN JJ: Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J. Pharmacol. Exp. Ther. (2005) 315:24-35.
   PubMed Web of Science ®Google Scholar
• POTTIER RH, KENNEDY JC: The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J. Photochem. Photobiol. B. (1990) 8:1-16.
   PubMed Web of Science ®Google Scholar
• KORBELIK M, HUNG J: Cellular delivery and retention of Photofrin II: the effects of interaction with human plasma proteins. Photochem. Photobiol. (1991) 53:501-510.
   PubMed Web of Science ®Google Scholar
• BRUNNER H, ARNDT MR, TREITTINGER B: Porphyrin platinum conjugates – new aims. Inorg. Chim. Acta. (2004) 357:1649-1669.
   Web of Science ®Google Scholar
• ALI H, VAN LIER JE: Metal complexes as photo- and radiosensitizers. Chem. Rev. (1999) 99:2379-2450.
   PubMed Web of Science ®Google Scholar
• BERJOT M, THEOPHANIDES T: Excitation profiles of soret-excited resonance raman spectra of platinum-hematoporphyrin complexes. Inorg. Chim. Acta, (1980) 46:281-284.
   Web of Science ®Google Scholar
• LOTTNER C, BART K-C, BERNHARDT G, BRUNNER H: Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity. J. Med. Chem. (2002) 45:2064-2078.
   PubMed Web of Science ®Google Scholar
• LOTTNER C, BART K-C, BERNHARDT G, BRUNNER H: Soluble tetraarylporphyrin-platinum conjugates as cytotoxic and phototoxic antitumor agents. J. Med. Chem. (2002) 45:2079-2089.
   PubMed Web of Science ®Google Scholar
• LOTTNER C, KNUECHEL R, BERNHARDT, BRUNNER H: Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates. Cancer Lett. (2004) 203:171-180.
   PubMed Web of Science ®Google Scholar
• LOTTNER C, KNUECHEL R, BERNHARDT, BRUNNER H: Distribution and subcellular localization of a water-soluble hematoporphyrin- platinum(II) complex in human bladder cancer cells. Cancer Lett. (2004) 215:167-177.
   PubMed Web of Science ®Google Scholar
• BRUNNER H, SCHELLERER K-M: Double porphyrin platinum conjugates. Z. Naturforsch. (2002) 57b:751-756.
   Google Scholar
• KLENER T, WINGEN F, KEPPLER BK, KREMPIEN B, SCHMAHL D: Anticancer agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer. Res. Clin. Oncol. (1990) 116:341-350.
   PubMed Web of Science ®Google Scholar
• BLOEMINK MJ, DIEDEREN JJ, DORENBOS JP, HEETEBRIJ RJ, KEPPLER BK, REEDIJK J: Calcium ions do accelerate the DNA binding of new antitumor-active platinum aminophosphonate complexes. Eur. J. Inorg. Chem. (1999) 1999:1655-1657.
   Google Scholar
• LAFORGIA M, CERAZINO L, MARGIOTTA et al.: Synthesis and characterization of platinum(II) complexes of diethyl[(methylsulfinyl)methyl] phosphonate: potential drugs against bone tumors. Eur. J. Inorg. Chem. (2004) 2004:3445-3452.
   Google Scholar
• GALANSKI M, SLABY S, JAKUPEC MA, KEPPLER BK: Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-bis(phos- phonomethyl)glycine ligand. J. Med. Chem. (2003) 46:4946-4951.
   PubMed Web of Science ®Google Scholar
• BAKALOVA A, BUYUKLIEV R, TCHOLAKOVA I, MOMEKOV G, KONSTANTINOV S, KARAIVANOVA M: Synthesis, physicochemical investigation and cytotoxic activity of new Pt(II) complexes with hydantoin ligands. Eur. J. Med. Chem. (2003) 38:627-632.
   PubMed Web of Science ®Google Scholar
• BAKALOVA A, BUYUKLIEV R, MOMEKOV G et al.: Synthesis, physicochemical and in vitro pharmacological investigation of new platinum(II) complexes with some cycloalkanespiro-5′-hydantoins. Eur. J. Med. Chem. (2005) 40:590-596.
   PubMed Web of Science ®Google Scholar
• WHITAKKER J, McFADYEN WD, WICKHAM G, WAKELIN GL, MURRAY V: The interaction of DNA-targeted platinum phenanthridinium complexes with DNA. Nucleic Acids Res. (1998) 26:3933-3939.
   PubMed Web of Science ®Google Scholar
• WHITAKKER J, MCFADYEN WD, BAGULEY BC, MURRAY V: The interaction of DNA-targeted platinum phenanthridinium complexes with DNA in human cells. Anticancer Drug Des. (2001) 16:81-89.
   PubMedGoogle Scholar
• TEMPLE MD, RECABARREN R, McFADYEN WD, HOLMES RJ, DENNY WA, MURRAY V: The interaction of DNA-targeted 9-aminoacridine-4-carboxamide platinum complexes with DNA in intact human cells. Biochi. Biophys. Acta. (2002) 1574:223-230.
   PubMedGoogle Scholar
• BROW JM, PLEATMAN CR, BIERBACH U: Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks. Bioorg. Med. Chem. Lett.. (2002) 12:2953-2955.
   PubMed Web of Science ®Google Scholar
• HESS SM, MOUNCE AM, SEQUEIRA RC, AUGUSTUS TM, ACKLEY MC, BIERBACH U: Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. Cancer Chemother. Pharmacol. (2005) 56:337-343.
   PubMed Web of Science ®Google Scholar
• ALDERDEN RA, MELLOR HR, MODOK S, HAMBLEY TW, CALLAGHAN R: Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug. Biochem. Pharmacol. (2006) 71:1136-1145.
   PubMed Web of Science ®Google Scholar
• LOSKOTOVA H, BRABEC V: DNA interactions of cisplatin tethered to the DNA minor groove binder distamycin. Eur. J. Biochem. (1999) 266:392-402.
   PubMedGoogle Scholar
• KRUSZEWSKI M, BOUZYK E, ODLAK T et al.: Differential toxic effects of cis-platinum(II) and palladium(II) chlorides complexed with methyl-3,4-diamine- 2,3,4,6-tetradeoxy-α-L-lyxo-hexapyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratogen. Carcinogen. Mutagen. (2003) (Suppl.1):1-11.
   PubMedGoogle Scholar
• GANGOPADHYAY SB, ROEDIGS A, BILL KANGARLOO S, KREBS B, WOLFF JE: Cellular accumulation determines the activity of three novel tricyclic platinum agents. Anticancer Res. (2001) 21:2039-2044.
   PubMed Web of Science ®Google Scholar
• MA D-L, CHE C-M: A bifunctional platinum(II) complex capable of intercalation and hydrogen-bonding interactions with DNA: binding studies and cytotoxicity. Chem. Eur. J. (2003) 9:6133-6144.
   PubMed Web of Science ®Google Scholar
• BRODIE C, COLLINS JG, ALDRICH-WRIGHT JR: DNA binding and biological activity of some platinum(II) intercalating compounds containing methyl-substituted 1,10-phenanthrolines. Dalton Trans. (2004) 8:1145-1152.
   Google Scholar
• McCLUSKEY A, ACKLAND SP, GARDINER E, WALKOM CC, SAKOFF JA: The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design? Anticancer Drug Des. (2001) 16:291-303.
   PubMedGoogle Scholar
• TO KK, HO YP, AU-YEUNG SC: Synergistic interaction between platinum-based antitumor agents and demethylcantharidin. Cancer Lett. (2005) 223:227-237.
   PubMed Web of Science ®Google Scholar
• TO KK, HO YP, AU-YEUNG SC: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents. Anticancer Drugs. (2005) 16:825-835.
   PubMed Web of Science ®Google Scholar
• BLAGLOW JE, MILLER RA: The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther. (2005) 4:6-13.
   PubMed Web of Science ®Google Scholar
• MILLET R, URIG S, JACOB J et al.: Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors. J. Med. Chem. (2005) 48:7024-7039.
   PubMed Web of Science ®Google Scholar